藥明生物(02269.HK)收購輝瑞中國生物藥原液和製劑生產基地
藥明生物(02269.HK)宣布,與輝瑞中國達成收購協議,將收購輝瑞中國位於杭州的先進生物藥生產基地,相關員工也將由藥明生物接收,交易預計在上半年完成,料將迅速提升藥明生物原液和製劑產能,滿足商業化生產服務需求。
該生物藥生產基地面積達5萬平方米,於2018年投入GMP生產,包括一條原液生產線和兩條製劑生產線,預期收購完成後,藥明生物將新增原液二十廠(2x2000升)、製劑九廠和製劑十廠,其中原液二十廠將拓展至4x2000升。
藥明生物首席執行官陳智勝表示,與輝瑞達成合作有助擴大全球生產版圖,目前產能面臨短缺。收購杭州生物藥生產基地將可迅速提升產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.